ICOS and metastatic melanoma: ICOS expression on Tregs after IL‐2 therapy and the presence of Tregs in tumor infiltrating lymphocytes (TILs) has been associated with poor clinical outcome in metastatic melanoma [74, 75], however ICOS presence on other TILs has been associated with better prognosis [76].